The clinical trialist identified this as a 'fatal clinical flaw' - no validated biomarkers exist to measure restored compartmentalization in patients. Without measurable endpoints, therapeutic approaches targeting subcellular localization cannot advance to clinical trials. Source: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47)
0
investigations
0
debates
debate:sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47
source
Scores
Priority
0.900
Market Price
0.500